Objective. To compare tumor necrosis factor-α (TNF-α) inhibitors to nonbiological disease-modifying
antirheumatic drugs (DMARD) for the risk of serious infection in Japanese patients …

To the Editor: Infliximab, a monoclonal antibody against tumor necrosis factor α (TNF-α), is
used in Japan for the treatment of patients with active rheumatoid arthritis that is resistant to …

Methotrexate (MTX), the anchor drug in the current treatment strategy for rheumatoid arthritis
(RA), was first approved for treatment of RA in Japan in 1999 at the recommended dose of 6…

Objective To establish proper management of Pneumocystis jiroveci pneumonia (PCP) in
rheumatoid arthritis (RA) patients treated with infliximab. PCP has been observed in 0.4% of …

Application of biological agents targeting tumor necrosis factor-α (TNF-α) caused a paradigm
shift in the treatment of rheumatoid arthritis (RA). The introduction of infliximab in 2003 and …

<p>Familial cold autoinflammatory syndrome, Muckle-Wells syndrome (MWS), and chronic,
infantile, neurological, cutaneous and articular (CINCA) syndrome are dominantly inherited …

The introduction of biological agents targeting tumor necrosis factor-alpha (TNF-α) has brought
about a paradigm shift in the treatment of rheumatoid arthritis (RA). Although these anti-…

Background We aimed to elucidate differences in the characteristics of patients with coronavirus
disease 2019 (COVID-19) requiring hospitalization in Japan, by COVID-19 waves, from …

… Ryuji Koike’s work was supported by a grantin-aid for scientific research from the Japan
Society for the Promotion of Science (19590530). Dr. Miyasaka’s work was supported by a grant-…

Introduction The objective of this study was to directly compare the safety of tocilizumab (TCZ)
and TNF inhibitors (TNFIs) in rheumatoid arthritis (RA) patients in clinical practice. …